New T Top Line Data
89% in OPTIC and OPTIC-X trials (OPTIC-X gave T to placebo recipients from OPTIC). Redosing for relapsed patients also showed results.
Took questions but since Q2 CC is next week they only focused on the trial results and wouldn't talk about impact on earnings, etc. My take is that the $1B plus peak market for T will be greatly increased due to retreatments. Hope to hear more on this at the Q2 (likely will) and possibly increased projections for this year and peak sales.
Worth listening to the presentation if you get a chance. Some of the photos of TED patients are graphic, so be warned.